Concord Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 605306, "name": "Concord Drugs", "stock_name": "Concord Drugs", "full_name": "Concord Drugs Ltd", "name_url": "stocks-analysis/concord-drugs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "76.10", "chg": 1.3, "chgp": "1.74%", "dir": 1, "prev_price": "74.80", "mcapval": "101.00 Cr", "mcap": "Micro Cap", "scripcode": 538965, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE858L01010", "curr_date": "Jul 08, 01:45 PM", "curr_time": "13:53 PM", "last_traded_at": "Jul 08, 01:45 PM IST", "bse_nse_vol": "741 ", "exc_status": "Active", "traded_date": "Jul 08, 2026", "traded_date_str": "2026 07 08", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Concord Drugs Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-hold-4093430", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ConcordDrugsLtd_mojoScore_4093430.png", "date": "2026-07-08 10:10:56", "description": "Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Concord Drugs Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-hold-4074956", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ConcordDrugsLtd_mojoScore_4074956.png", "date": "2026-06-27 10:10:34", "description": "Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 June 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Concord Drugs Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-hold-by-marketsmojo-4056008", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ConcordDrugsLtd_mojoScore_4056008.png", "date": "2026-06-16 10:10:04", "description": "Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Concord Drugs Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-hold-by-marketsmojo-4036037", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ConcordDrugsLtd_mojoScore_4036037.png", "date": "2026-06-04 10:10:04", "description": "Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 04 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Concord Drugs Ltd Valuation Shifts to Attractive Amid Strong Market Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-attractive-amid-strong-market-performance-4025248", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ConcordDrugsLtd_valuationdot_4025248.png", "date": "2026-06-01 08:03:32", "description": "Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to an attractive territory, driven by evolving price-to-earnings and price-to-book value metrics. This transition comes alongside robust stock performance that has significantly outpaced the Sensex over the past year, signalling renewed investor interest in this micro-cap pharmaceutical player." }, { "title": "Concord Drugs Gains 5.98%: Key Financial Turnaround Drives Weekly Rally", "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-gains-598-key-financial-turnaround-drives-weekly-rally-4023352", "imagepath": "", "date": "2026-05-30 16:11:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 25:</strong> Modest price gain of 0.31% amid broad market rally</p>\n <p><strong>May 26:</strong> Sharp 4.87% jump following positive market reaction to quarterly results</p>\n <p><strong>May 27:</strong> Slight dip of 0.18% despite Sensex recovery</p>\n <p><strong>May 29:</strong> Continued gains of 0.93% amid market volatility and strong financial disclosures</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.77.74</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week ..." }, { "title": "Concord Drugs Ltd Reports Strong Quarterly Financial Turnaround Amid Market Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-reports-strong-quarterly-financial-turnaround-amid-market-volatility-4019131", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordDrugsLtd_fintrenddot_4019131.png", "date": "2026-05-29 08:00:23", "description": "Concord Drugs Ltd has demonstrated a marked improvement in its financial performance for the quarter ended March 2026, signalling a significant turnaround from previous periods. The company’s revenue, profitability, and earnings per share have all reached their highest quarterly levels in recent history, reflecting a very positive shift in its financial trend and investor sentiment." }, { "title": "Are Concord Drugs Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-concord-drugs-ltd-latest-results-good-or-bad-4018950", "imagepath": "", "date": "2026-05-28 19:23:27", "description": "Concord Drugs Ltd reported its Q4 FY26 financial results, showcasing significant growth in both net sales and net profit. The company achieved net sales of ₹37.90 crores, reflecting a year-on-year growth of 264.77%, marking a substantial recovery from the previous year's decline. This surge in revenue indicates either successful order fulfillment or notable market share gains. Additionally, the net profit for the quarter reached ₹0.53 crores, which is a remarkable increase of 1,225.00% compared to the same quarter last year, suggesting a turnaround in profitability.\n\nHowever, despite this impressive topline growth, the operational metrics raise concerns about the sustainability of such performance. The operating profit margin stood at 3.93%, a significant decrease from previous periods, indicating that the revenue growth did not translate into improved profitability. The profit after tax (PAT) margin of 1.4..." }, { "title": "Concord Drugs Q4 FY26: Explosive Revenue Growth Masks Persistent Profitability Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/concord-drugs-q4-fy26-explosive-revenue-growth-masks-persistent-profitability-concerns-4018101", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordDrugs_quaterlyResult_4018101.png", "date": "2026-05-27 23:46:26", "description": "Concord Drugs Limited, a Telangana-based pharmaceutical manufacturer specialising in finished formulations and injectables, reported a dramatic surge in quarterly revenues for Q4 FY26, with net sales soaring 264.77% year-on-year to ₹37.90 crores. Net profit jumped to ₹0.53 crores from ₹0.04 crores in the year-ago quarter, marking a 1,225.00% YoY increase. Despite this explosive topline growth, the micro-cap company with a market capitalisation of ₹107.00 crores continues to grapple with razor-thin profitability margins and structural challenges that have plagued its financial performance over the past five years." } ], "total": 291, "sid": "605306", "stock_news_url": "https://www.marketsmojo.com/news/concord-drugs-605306" }, "announcements": [ { "caption": "Closure of Trading Window", "datetime": "25-Jun-2026", "details": "Closure of Trading Window", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "01-Jun-2026", "details": "Copy of Newspaper publication for audited results for year ended 31st March2026.", "source": "BSE" }, { "caption": "Financial Results For Year Ending 31St March2026", "datetime": "29-May-2026", "details": "Financial Results for Year ending 31st March 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

May 25: Modest price gain of 0.31% amid broad market rally

May 26: Sharp 4.87% jump following positive market reaction to quarterly results

May 27: Slight dip of 0.18% despite Sensex recovery

May 29: Continued gains of 0.93% amid market volatility and strong financial disclosures

Week Open

Rs.77.74

Week ...

Read full news article

Concord Drugs Ltd Reports Strong Quarterly Financial Turnaround Amid Market Volatility

2026-05-29 08:00:23

Concord Drugs Ltd has demonstrated a marked improvement in its financial performance for the quarter ended March 2026, signalling a significant turnaround from previous periods. The company’s revenue, profitability, and earnings per share have all reached their highest quarterly levels in recent history, reflecting a very positive shift in its financial trend and investor sentiment.

Read full news article

Are Concord Drugs Ltd latest results good or bad?

2026-05-28 19:23:27

Concord Drugs Ltd reported its Q4 FY26 financial results, showcasing significant growth in both net sales and net profit. The company achieved net sales of ₹37.90 crores, reflecting a year-on-year growth of 264.77%, marking a substantial recovery from the previous year's decline. This surge in revenue indicates either successful order fulfillment or notable market share gains. Additionally, the net profit for the quarter reached ₹0.53 crores, which is a remarkable increase of 1,225.00% compared to the same quarter last year, suggesting a turnaround in profitability. However, despite this impressive topline growth, the operational metrics raise concerns about the sustainability of such performance. The operating profit margin stood at 3.93%, a significant decrease from previous periods, indicating that the revenue growth did not translate into improved profitability. The profit after tax (PAT) margin of 1.4...

Read full news article

Concord Drugs Q4 FY26: Explosive Revenue Growth Masks Persistent Profitability Concerns

2026-05-27 23:46:26

Concord Drugs Limited, a Telangana-based pharmaceutical manufacturer specialising in finished formulations and injectables, reported a dramatic surge in quarterly revenues for Q4 FY26, with net sales soaring 264.77% year-on-year to ₹37.90 crores. Net profit jumped to ₹0.53 crores from ₹0.04 crores in the year-ago quarter, marking a 1,225.00% YoY increase. Despite this explosive topline growth, the micro-cap company with a market capitalisation of ₹107.00 crores continues to grapple with razor-thin profitability margins and structural challenges that have plagued its financial performance over the past five years.

Read full news article